Zhongzhu Healthcare 

Zhongzhu Healthcare Holding Co.,Ltd primarily focuses on real estate development and construction across China. Within the healthcare sector, its activities encompass the manufacturing of ophthalmic pharmaceuticals and dedicated research into natural botanical medications. The company is also actively engaged in the development of specific drugs, such as recombinant human endostatin adenovirus injection for anti-cancer gene therapy, Genistein capsules targeting postmenopausal osteoporosis, and motherwort-based treatments for gynecological conditions. Furthermore, it provides a comprehensive array of medical instruments, including solutions for radiation therapy, hyperthermia, phototherapy, and ultrasound diagnostics, alongside developing cutting-edge imaging systems for breast tumor detection. Complementing these ventures, the company also offers various medical services. Established in 1970 and based in Qianjiang, China, the entity rebranded from Zhongzhu Holding Co., Ltd. to its current name, Zhongzhu Healthcare Holding Co.,Ltd, in June 2016.